Global Information
회사소개 | 문의

반려동물용 동물의약품(2017년)

Animal Pharm Medicines for Companion Animals 2017

리서치사 Animal Pharm
발행일 2017년 12월 상품 코드 594573
페이지 정보 영문 77 Pages
가격
US $ 2,650 ₩ 2,991,300 PDF by E-mail (Single User License)
US $ 7,950 ₩ 8,973,900 PDF by E-mail (Global License)


반려동물용 동물의약품(2017년) Animal Pharm Medicines for Companion Animals 2017
발행일 : 2017년 12월 페이지 정보 : 영문 77 Pages

한글목차

반려동물용 동물의약품 시장에 대해 조사했으며, 현재·향후 시장 동향, 활발한 의약품 기업, 반려동물용 의약품의 규제, 통증 치료·관리에 대한 접근 및 일반적인 질환의 치료 등에 대해 분석하여 전해드립니다.

개요

제1장 서론

  • 동물의약품 산업
  • 반려동물 시장
  • 요약

제2장 활발한 반려동물용 의약품 기업

  • ZOETIS
  • BOEHRINGER INGELHEIM(+ MERIAL)
  • MERCK/MSD ANIMAL HEALTH
  • ELANCO
  • BAYER ANIMAL HEALTH
  • VIRBAC
  • VETOQUINOL
  • DECHRA PHARMACEUTICALS
  • ARATANA THERAPEUTICS
  • NIPPON ZENYAKU KOGYO

제3장 반려동물 의약품의 규제

  • 미국·EU의 규제기관
  • 규제 가이던스
  • 반려동물 의약품의 가용성
  • 무인가 의약품의 사용
  • 기타 지역의 개요

제4장 통증의 치료와 관리

  • 통증의 평가
  • 통증 치료제
  • 현재 개발중인 동물용 제품

제5장 애완동물의 암치료

  • 암치료의 평가
  • 현재 이용 가능한 암 치료제
  • 암 치료제의 향후 동향

제6장 알레르기성 피부질환

  • 알레르기성 피부질환의 평가
  • 알레르기성 피부질환 치료제

제7장 심혈관질환

  • 심혈관질환의 평가
  • 심장 치료제
  • 심혈관 치료제의 향후 동향

제8장 항균제 : 딜레마

  • 항균제의 이용 및 저항력의 발달
  • 항균제의 향후 동향

제9장 요약

KSA 18.01.09

영문목차

This unique report will help companies develop strategies to meet the growing needs of the companion animal sector. The global veterinary drugs market is expected to exhibit a 5.1% compound annual growth rate from 2016-2024. The fastest growth is expected to be in the companion animal sector in economies including the US, BRazil, China and Russia.

The global trend of rising pet ownership increases the demand for pharmaceutical innovations in this sector. This report focuses on two of the world's most popular pets - cats and dogs.

Key insights include:

  • Current and future market trends
  • Active pharmaceutical companies
  • Regulation of companion animal medicine
  • Approaches to pain treatment and management
  • Treatment of common disorders

Table of Contents

Contents

Executive Summary

Introduction

  • 1.1. The Animal Health Industry
  • 1.2. The Companion Animal Sector
    • 1.2.1. Changes in Pet Ownership
    • 1.2.2. The Future of Companion Animal Health in Developed Markets
    • 1.2.3. The Future of Companion Animal Health in Emerging Markets
  • 1.3. Summary

Chapter 2: The Pharmaceutical Companies Active in Companion Animals

  • 2.1. ZOETIS
  • 2.2. BOEHRINGER INGELHEIM (+ MERIAL)
  • 2.3. MERCK/MSD ANIMAL HEALTH
  • 2.4. ELANCO
  • 2.5. BAYER ANIMAL HEALTH
  • 2.6. VIRBAC
  • 2.7. VETOQUINOL
  • 2.8. DECHRA PHARMACEUTICALS
  • 2.9. ARATANA THERAPEUTICS
  • 2.10. NIPPON ZENYAKU KOGYO

Chapter 3: Regulation of Companion Animal Medicines

  • 3.1. The United States (US) and European (EU) Regulatory Authorities
  • 3.2. Regulatory Guidance
  • 3.3. Availability of Companion Animal Medicines
  • 3.4. Use of Unlicensed Medicinal Products
  • 3.5. Overview of Other Regions
    • 3.5.1. BRAZIL
    • 3.5.2. RUSSIA
    • 3.5.3. INDIA
    • 3.5.4. CHINA

Chapter 4: Treatment and Management of Pain

  • 4.1. Evaluating Pain
    • 4.1.1. Future Trends in Assessing Pains
  • 4.2. Pain Therapeutics
    • 4.2.1. Opioids
      • 4.2.1.1. Future Trends for Opiods:
    • 4.2.2. Non-steroidal anti-inflammatory drugs
      • 4.2.2.1. Future trends for NSAIDs
    • 4.2.3. Local anaesthetics
    • 4.2.4. Other analgesics with currently approved veterinary products
    • 4.2.5. Other analgesics without currently approved veterinary products
  • 4.3. Products currently in development for veterinary application

Chapter 5: Treatment of Pet Cancer

  • 5.1. Assessing Cancer Therapies
  • 5.2. Currently Available Cancer Treatments
  • 5.3. Future Trends for Cancer therapy

Chapter 6: Allergic Skin Disorders

  • 6.1. Evaluating Allergic Skin Disease
  • 6.2. Allergic Dermatitis Therapeutics
    • 6.2.1. ACUTE DISEASE FLARES
    • 6.2.2. CHRONIC DISEASE
    • 6.2.3. THE PRODUCTS
    • 6.3. Future trends and products currently in development for the treatment of allergic skin disease.

Chapter 7: Cardiac Disorders

  • 7.1. Assessing Cardiovascular Disease
  • 7.2. Cardiology Therapeutics
    • 7.2.1. Diuretics
    • 7.2.2. Spironolactone
    • 7.2.3. ACE Inhibitors
    • 7.2.4. Pimobendan
    • 7.2.5. Calcium Channel Blockers
    • 7.2.6. Methylxanthines
  • 7.3. Future Trends for Cardiovascular Drugs

Chapter 8: Antimicrobials: A Dilemma

  • 8.1. Antimicrobial use and the Development of Resistance
    • 8.1.1. Antimicrobial prescribing habits and use in companion animal veterinary medicine
  • 8.2. Future trends for antimicrobials

Chapter 9: Summary

References

List of Figures

  • Figure 1: Estimated human equivalent ages for older pets
  • Figure 2: Prevalence of hip dysplasia in a selection of breeds, reproduced from King, 2017.(Data from Orthopedic Foundation for Animals.)
  • Figure 3: Colorado State University canine pain scale
  • Figure 4: An excerpt of the FMPI reproduced from Gruen et al., 2015
  • Figure 5: Voyce Pro dog collar
  • Figure 6: Canine osteosarcoma, reproduced from Biller et al., 2016
  • Figure 7: Image of dog with lymphoma, notice enlarged lymph nodes under jaw
  • Figure 8: Canine Atopic Dermatitis, reproduced from Olivry et al., 2010
  • Figure 9: The CADESI-03 Scale, reproduced from Olivry et al., 2007
  • Figure 10: PVAS, reproduced from Olivry et al., 2007
  • Figure 11: The CADLI, reproduced from Plant et al., 2012
  • Figure 12: Body regions assessed by the SCORFAD Scale, reproduced from Steffan et al., 2012
  • Figure 13: How heart disease affects different body functions
  • Figure 14: Radiographic image of heart enlargement
  • Figure 15: Canine electrocardiography
  • Figure 16: Canine echocardiography

List of Tables

  • Table 1: Number of dogs and cats in the Top 20 pet owning countries
  • Table 2: Companion Animal therapeutic area guidelines issued by the EMA and FDA CVM
  • Table 3: Multifactorial CMIs for chronic pain assessment in veterinary medicine
  • Table 4: Common locations of pet cancers
  • Table 5: Tabs vs mAbs
  • Table 6: Frequency of use of different antimicrobials
  • Table 7: The antibiotics mentioned and frequency with which they were mentioned for the top five indications where antibiotics are said to be prescribed for use in cats
  • Table 8: The antibiotics mentioned and frequency with which they were mentioned for the top five indications where antibiotics are said to be prescribed for use in dogs
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research